Caution with DDAVP
In March, Health Canada approved desmopressin acetate (DDAVP) for use in Canada to prevent chronic bedwetting in children. Manufactured by Ferring Pharmaceuticals, desmopressin acetate is a synthetic structural analogue of the natural human hormone, arginine vasopressin, which as an antidiuretic sometimes used in the treatment of diabetes insipidus and certain types of hemophilia. Arginine vasopressin limits the production of urine.
The Compendium of Pharmaceuticals and Specialties [Canadian Pharmacists Association/Association des pharmaciens du Canada] notes that its side effects may include headache, abdominal cramps and nausea, and lists dizziness, chills, wheezing, rash, and edema (swelling) of the face and hands, water intoxication, and changes in blood pressure among possible adverse effects.
The Internet site of the Harvard Medical School includes the possibility of "rare severe allergic reaction", and seizures and coma in severe cases. It also notes that "adverse reactions may be more likely and more severe in children under the age of 18."
The US Food and Drug Administration (FDA) says that "studies with DDAVP have not been performed to evaluate carcinogenic potential, mutagenic potential or effects on fertility."
Reuters Health states that "carbamazepine may potentiate antidiuretic effects of desmopressin. Anaphylaxis has occurred with IV administration."
Information
|
